WILMINGTON, Mass. & DENVER--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Related Sciences (“RS”), a data science-driven drug discovery firm, today announced a multi-program collaboration agreement to apply Logica™ across several previously undrugged targets in the RS portfolio.

马萨诸塞州威尔明顿（WILMINGTON），数据科学驱动的药物发现公司Charles River Laboratories International，Inc。（NYSE:CRL）和相关科学（“RS”）今天宣布了应用Logica的多项目合作协议™ 在RS组合中的几个以前没有严格规定的目标。

Logica is an Artificial Intelligence (AI) powered drug solution that translates biological insights into optimized assets..

Logica是一种人工智能（AI）动力药物解决方案，可将生物学见解转化为优化资产。。

Under the collaboration, RS will work closely with the Charles River and Valo Health teams to deploy Logica to discover valuable new medicines to address key unmet needs across a range of disease areas, including cancer immunotherapy, autoimmunity, and inflammatory diseases.

在合作下，RS将与Charles River和Valo Health团队密切合作，部署Logica，发现有价值的新药，以解决癌症免疫治疗，自身免疫和炎症性疾病等一系列疾病领域的关键未满足需求。

“Partnering with the team at Related Sciences, we are excited to deploy Logica in the hunt for first-in-class therapeutics,” said Julie Frearson, PhD, Senior Vice President and Chief Scientific Officer, Charles River. “Logica’s unique platform, which combines AI/machine learning (ML)-enabled in silico discovery, high-powered DNA-encoded libraries, and traditional screening techniques, has the capability to accelerate the drug discovery and development pipeline, transforming a target to a candidate in just over two years.”.

Charles River高级副总裁兼首席科学官Julie Frearson博士说：“与相关科学团队合作，我们很高兴在寻找一流疗法方面部署Logica。”。“Logica独特的平台结合了AI/机器学习（ML）启用的计算机发现，高功率DNA编码库和传统筛选技术，能够加速药物发现和开发流程，将目标转变为候选人在短短两年内“。

“Across our growing portfolio, Related Sciences brings together specialized technologies and orthogonal screening approaches that can maximize our chances of discovering transformational new medicines against high value targets,” said Adam Kolom, Founder and CEO of Related Sciences. “Logica’s combination of advanced AI/ML and state-of-the-art hit finding approaches, within a unique risk-sharing business model, pairs beautifully with Related Sciences’ data science-driven, multi-technology approach to drug discovery.”.

“在我们不断增长的投资组合中，相关科学汇集了专业技术和正交筛选方法，可以最大限度地发现针对高价值目标的转型新药，”相关科学创始人兼首席执行官Adam Kolom说。“Logica将先进的AI/ML和最先进的命中发现方法相结合，在独特的风险共享业务模型中，与相关科学的数据科学驱动，多技术的药物发现方法完美配对。”。

Logica: Redefining Small Molecule Drug Discovery’s Gold Standard

Logica：重新定义小分子药物发现的黄金标准

In 2022, Charles River and Valo Health launched Logica, leveraging the AI-powered Valo Opal Computational PlatformTM and Charles River’s leading preclinical expertise, providing clients with transformed drug discovery with a single integrated offering seamlessly translating targets to candidate nomination.

2022年，Charles River和Valo Health推出了Logica，利用AI支持的Valo Opal计算平台TM和Charles River领先的临床前专业知识，为客户提供转型的药物发现，提供单一集成，无缝翻译目标以候选提名。

Logica is offered as a fully managed, risk-sharing model, with most of the client cost tied to success..

Logica作为完全管理的风险共享模型提供，大部分客户成本与成功相关。。

Logica utilizes industry-leading predictive models, chemical design, and synthesis capabilities, DNA-encoded libraries, in silico high throughput screening from Valo’s Opal Computational Platform as well as Charles River’s leading capabilities in all aspects of discovery optimization including high throughput screening, medicinal chemistry, ADME, biology, pharmacology, and ultimately safety testing and IND submission, joining together for the first time to create a computation-powered, unified target-to-candidate offering..

Logica利用行业领先的预测模型，化学设计和合成能力，DNA编码库，Valo Opal计算平台的计算机高通量筛选以及Charles River在发现优化各个方面的领先能力，包括高通量筛选，药物化学，ADME，生物学，药理学，并最终进行安全测试和IND提交，首次结合在一起创建一个计算功能强大的统一目标候选产品。。

Last year, Charles River and Flagship’s Pioneering Medicines announced an agreement to deploy Logica across a portfolio of targets with the aim of creating optimized small molecules that lead to novel therapies for unmet medical needs.

去年，Charles River和Flagship的开拓性药品宣布达成协议，在一系列目标中部署Logica，旨在创建优化的小分子，为未满足的医疗需求提供新的治疗方法。

About Related Sciences

关于相关科学

Related Sciences (RS) is a data science-driven drug discovery firm. RS uses a proprietary AI/ML platform to identify the best new drug discovery opportunities for every disease, assembles decentralized teams of top global researchers to guide the science, and then invests in and leads the efficient discovery of valuable new medicines via preclinical-specialized R&D platforms.

相关科学（RS）是一家数据科学驱动的药物发现公司。RS使用专有的AI/ML平台来确定每种疾病的最佳新药发现机会，组装分散的全球顶级研究人员团队来指导科学，然后通过临床前专业研发投资并领导有价值新药的有效发现平台。

RS is led by an interdisciplinary team of drug discovery, data science, and finance veterans and is backed by a luminary group of investors. www.related.vc.

RS由药物发现，数据科学和金融退伍军人组成的跨学科团队领导，并得到腔内投资者的支持。www.related.vc。

About Valo Health

关于瓦洛健康

Valo Health, Inc (Valo) is a technology company built to transform the drug discovery and development process using human-centric data and AI-driven computation. As a digitally native company, Valo aims to fully integrate human-centric data across the entire drug development lifecycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing the costs, time, and failure rates.

Valo Health，Inc（Valo）是一家科技公司，致力于利用以人为本的数据和AI驱动的计算来改变药物发现和开发过程。作为一家数字本土公司，Valo旨在将整个药物开发生命周期中以人为中心的数据完全整合到一个统一的体系结构中，从而加速生命变化药物的发现和开发，同时降低成本，时间和故障率。

The company’s Opal Computational Platform™ consists of an integrated set of capabilities designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs across cardiovascular-metabolic-renal, oncology, and neurodegenerative disease.

公司的蛋白石计算平台™ 由一套集成的功能组成，旨在将数据转化为有价值的见解，从而加速发现并使Valo能够推进跨越心血管-代谢-肾脏，肿瘤学和神经退行性疾病的强大计划流程。

Founded by Flagship Pioneering and headquartered in Boston, MA, Valo also has offices in Lexington, MA, and New York, NY. To learn more, visit www.valohealth.com..

Valo由Flagship开拓公司创立，总部设在马萨诸塞州波士顿，还在马萨诸塞州列克星敦和纽约州设有办事处。要了解更多信息，请访问www.valohealth.com。。

About Charles River

关于查尔斯河

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

查尔斯河提供必要的产品和服务，帮助制药和生物技术公司，政府机构和全球领先的学术机构加速他们的研究和药物开发工作。我们的专职员工专注于为客户提供他们需要改进的内容，并为需要他们的患者加快发现，早期开发和安全制造新疗法。

To learn more about our unique portfolio and breadth of services, visit www.criver.com..

要了解更多有关我们独特的产品组合和广泛的服务，请访问www.criver.com。。